A Prospective, Single Arm Study of the Hansen System for Introducing and Positioning the Thermocool Catheter in Patients With Paroxysmal Atrial Fibrillation

The purpose of this study is to assess the safety and performance of the Hansen Medical Sensei Robotic System and Artisan Catheter when used to robotically manipulate the Biosense ThermoCool ablation catheter for the treatment of paroxysmal atrial fibrillation (irregular heartbeats originating in the upper chambers of the heart). The Biosense ThermoCool catheter is FDA approved for use in ablation therapy. The Hansen Medical Robotic Sensei System and Artisan catheter are approved in Europe for use during ablation procedures. This system has been used to treat atrial fibrillation in over 1000 patients worldwide by navigating existing, approved ablation catheters. In the US the Hansen Sensei System with Artisan catheter has FDA clearance as a robotic delivery system to facilitate manipulation, positioning and control of catheters used to collect electrophysiological data within the heart atria (upper chambers or the heart), but has not been studied or approved in the US for use in ablation treatment. This study is designed to evaluate safety, compatibility and effectiveness when the Hansen system is used with the ThermoCool ablation catheter in the treatment of paroxysmal atrial fibrillation. In this prospective,nonrandomized study, subjects will undergo treatment with robotic delivery of the of the ThermoCool ablation catheter. The primary effectiveness and safety outcomes must meet pre-established Target Performance Goals(chronic success rate is at least 54%; and, the major complication rate is no greater than 16%).

Stanford is now accepting new patients for this trial. Please contact Amin Al-Ahmad at 6507237111 for more information.

Investigator(s):

Intervention(s):

  • device : Ablation

Phase: N/A

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

1. Subjects with paroxysmal atrial fibrillation who have had two or more spontaneously terminating episodes of atrial fibrillation, that last longer than 30 seconds and shorter than 7 days, in the nine months prior to enrollment. At least one episode must be documented with EKG, TTM, Holter monitor, or telemetry. 2. Failure of at least one Class I - IV anti-arrhythmic drug (AAD) for PAF as evidenced by recurrent symptomatic PAF, or intolerable side effects due to AADs. AADs are defined in Appendix B. 3. Signed informed consent. 4. Age 18 years or older 5. Able and willing to comply with all pre-, post-, and follow-up testing and requirements.

External Links

Explore related trials

Contact information

Primary Contact:

Amin Al-Ahmad 6507237111

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: